Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 441 | 0.73 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3402
Sealed predictions
- CAMKK2 in dopamine neurons, braak-0.35 (p 0.349) → -0.33 (p 0.386)receipt 3411
Swarm cases
receipt 3411: CAMKK2 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.123, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.38 (p 0.123, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.036, n 18). not the mix.
- skeptic
- leave-one-out range -0.52 to -0.29, sign flips 0; without severely affected donors -0.38 (p 0.123, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0099, n 18) vs -0.38 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CAMKK2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CAMKK2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.65 p 0.021 (needs p < 5.3e-4)
Receipts
loading the receipts